Articles related to ALZHEIMER'S/DEMENTIA

The results underscore a clear message: timing and patient selection are key — and early diagnosis and intervention make the biggest difference.

For the first time, researchers found that empagliflozin, an established diabetes and heart medication, reduced markers of brain injury while restoring blood flow in critical brain regions.

Patients, with or without anemia, should be screened for elevated homocysteine or B12 deficiency because that may be one of the reversible factors in their cognitive decline.

POINTER and FINGER are the first large-scale randomized trials to test multi-domain lifestyle interventions—like exercise, diet, cognitive training, and social engagement.

The findings stress the importance of diagnosis timing in neurodegenerative risk modeling and suggest that both early-life exposures and recent comorbidities contribute to disease vulnerability.

“We’re the first to show that Chlamydia pneumoniae can go directly up the nose and into the brain where it can set off pathologies that look like Alzheimer’s disease. We saw this happen in a mouse model, and the evidence is potentially scary for humans as well.” – James St. John, Neuroscientist